JAAD online
Ovicidal efficacy of high concentration dimeticone: A new era of head lice treatment

https://doi.org/10.1016/j.jaad.2010.04.003Get rights and content

References (5)

  • J. Heukelbach et al.

    A highly efficacious pediculicide based on dimeticone: randomized observer blinded comparative trial

    BMC Infectious Diseases

    (2008)
  • I.F. Burgess

    Current treatments for pediculosis capitis

    Curr Opin Infect Dis

    (2009)
There are more references available in the full text version of this article.

Cited by (29)

  • Ectoparasites: Pediculosis and tungiasis

    2020, Journal of the American Academy of Dermatology
  • Efficacy and safety of dimeticones in the treatment of epidermal parasitic skin diseases with special emphasis on tungiasis: an evidence-based critical review

    2020, Brazilian Journal of Infectious Diseases
    Citation Excerpt :

    If the application time was reduced to 10 min, 5–8% of the embryos survived and developed into adults. When 9–11 days old head lice eggs were treated with NYDA®, the efficacy of killing lice embryos was reduced to 97%.24,25 Anecdotal observations suggest that pubic lice are also highly susceptible to treatment with NYDA®.26

  • Update on parasitic dermatoses

    2020, Anais Brasileiros de Dermatologia
    Citation Excerpt :

    The application should be repeated in seven to ten days. It has ovicidal action.24–26 Ivermectin topical 0.5% lotion was approved by the FDA in 2012 for the treatment of children aged 6 months or older.

View all citing articles on Scopus

Supported by G. Pohl-Boskamp GmbH & Co. KG (Hohenlockstedt, Germany). Dr Heukelbach is a research fellow from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq/Brazil). Dr Sonnberg was supported by the German Research Foundation, PhD program (Graduiertenkolleg) 793.

Conflicts of interest: Dr Heukelbach has been scientific consultant to G. Pohl-Boskamp GmbH & Co. KG, the manufacturer of NYDA. Dr Speare has been scientific consultant in the past to Emerald Forest Pharmaceuticals in trials on plant-based pediculicides, but currently has no links to the pharmaceutical industry. The other authors do not have any conflicts of interest to declare.

View full text